FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

Coverage, in order

1. 6d ago
   FDA Drug Safety / Drugs feed indie

   FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

   On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated appro

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.